Long-Term Health Economic Evaluation of Intermittently Scanned Glucose Monitoring Compared with Self-Monitoring Blood Glucose in a Real-World Setting in Finnish Adult Individuals with Type 1 Diabetes
Main finding · Cost-effectivenessResult — go to the resultIncremental cost-effectiveness ratio 9396 EUR per QALY gainedAuthors' conclusion
According to the present analysis, the use of isCGM is considered cost-effective in adult individuals with type 1 diabetes in a real-world setting in Finland.
Study context
- Population
- Adults with T1D, real-world cohort from Eastern Finland; mean age 48 years, mean diabetes duration 25.8 years, mean baseline HbA1c 8.6%real-world cohort
- Participants
- 877 adults
- Exposure
- Intermittently scanned continuous glucose monitoring (isCGM) vs SMBG
- Outcome
- Long-term cost-effectiveness (incremental cost-effectiveness ratio per QALY gained)
- Follow-up
- Lifetime
Methodological detailsIQVIA Core Diabetes Model (v10.0), real-world cohort input data, lifetime time horizon, 3% discount rate
- IQVIA Core Diabetes Model (v10.0)
- Real-world cohort input data
- Lifetime time horizon
- 3% discount rate
Main finding
Cost-effectiveness
Incremental cost-effectiveness ratio
9396 EUR per QALY gained
As reported in the abstract
- Quality-adjusted life year (QALY) gain with isCGM
- 0.84 QALYs
- Higher direct lifetime costs with isCGM
- 7861 EUR
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Observed 12-month change in HbA1c after isCGM initiation (model input) | isCGM mean −0.37 % |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Long-Term Health Economic Evaluation of Intermittently Scanned Glucose Monitoring Compared with Self-Monitoring Blood Glucose in a Real-World Setting in Finnish Adult Individuals with Type 1 Diabetes. Diabetes Technol Ther. Published 4 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →